Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 19, 2017 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM)

CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 19, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation...
June 05, 2017 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference

CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 5, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation...
May 02, 2017 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study

CAMBRIDGE, MASSACHUSETTS--(Marketwired - May 2, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI") today provided an update on its cytomegalovirus ("CMV") Phase I clinical study,...
April 05, 2017 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress

CAMBRIDGE, MASSACHUSETTS--(Marketwired - April 5, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present updates on two of its programs at the World Vaccine...
March 30, 2017 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines Appoints Avi Mazaltov as Global Head of Manufacturing and SciVac General Manager; Rehovot, Israel Site

CAMBRIDGE, MASSACHUSETTS--(Marketwired - March 30, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") and SciVac Ltd. ("SciVac"), a wholly owned subsidiary of VBI, are pleased to...
February 22, 2017 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Feb. 22, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") announced today that the Biologics and Genetic Therapies Directorate (BGTD) of...
February 07, 2017 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical Study

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Feb. 7, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI") announced today the receipt of positive Scientific Advice from the Committee for...
December 06, 2016 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Dec. 6, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI"), a clinical-stage biopharmaceutical company developing infectious disease and...
November 14, 2016 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vac(TM) Hepatitis B Vaccine

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Nov. 14, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today reported interim results from an ongoing Phase IV postmarketing study to...
November 10, 2016 08:30 ET | Source: VBI Vaccines Inc.

VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Nov. 10, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the Society of Neuro-Oncology Annual Meeting on...